NO891122L - Platinakoordinasjonsforbindelser og anvendelse av forbindelsene i kjemoterapi. - Google Patents
Platinakoordinasjonsforbindelser og anvendelse av forbindelsene i kjemoterapi.Info
- Publication number
- NO891122L NO891122L NO89891122A NO891122A NO891122L NO 891122 L NO891122 L NO 891122L NO 89891122 A NO89891122 A NO 89891122A NO 891122 A NO891122 A NO 891122A NO 891122 L NO891122 L NO 891122L
- Authority
- NO
- Norway
- Prior art keywords
- platinum
- compounds
- loperamide
- compound
- preparation
- Prior art date
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 title claims description 23
- 150000001875 compounds Chemical class 0.000 title claims description 21
- 238000002560 therapeutic procedure Methods 0.000 title description 2
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 claims description 18
- 229960001571 loperamide Drugs 0.000 claims description 18
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 229910052697 platinum Inorganic materials 0.000 claims description 9
- 150000003058 platinum compounds Chemical class 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 229960004562 carboplatin Drugs 0.000 claims description 5
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 claims description 2
- CCQPAEQGAVNNIA-UHFFFAOYSA-N cyclobutane-1,1-dicarboxylic acid Chemical compound OC(=O)C1(C(O)=O)CCC1 CCQPAEQGAVNNIA-UHFFFAOYSA-N 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 150000002690 malonic acid derivatives Chemical class 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- -1 platinum(II) compound Chemical class 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- WIBKDBYFIKUYJQ-UHFFFAOYSA-J azane;platinum(4+);dichloride;dihydroxide Chemical compound N.N.[OH-].[OH-].[Cl-].[Cl-].[Pt+4] WIBKDBYFIKUYJQ-UHFFFAOYSA-J 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- FAYYOWYEIMGNGO-UHFFFAOYSA-N butanamide;piperidine Chemical compound CCCC(N)=O.C1CCNCC1 FAYYOWYEIMGNGO-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- KDSNLYIMUZNERS-UHFFFAOYSA-N isobutyl amine Natural products CC(C)CN KDSNLYIMUZNERS-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- NDBYXKQCPYUOMI-UHFFFAOYSA-N platinum(4+) Chemical class [Pt+4] NDBYXKQCPYUOMI-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB888806224A GB8806224D0 (en) | 1988-03-16 | 1988-03-16 | Platinum chemotherapeutic product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO891122D0 NO891122D0 (no) | 1989-03-15 |
| NO891122L true NO891122L (no) | 1989-09-18 |
Family
ID=10633521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO89891122A NO891122L (no) | 1988-03-16 | 1989-03-15 | Platinakoordinasjonsforbindelser og anvendelse av forbindelsene i kjemoterapi. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4892735A (de) |
| EP (1) | EP0339772A1 (de) |
| JP (1) | JPH0296523A (de) |
| KR (1) | KR890014107A (de) |
| AU (1) | AU613720B2 (de) |
| DK (1) | DK105889A (de) |
| FI (1) | FI890951A (de) |
| GB (1) | GB8806224D0 (de) |
| IL (1) | IL89502A0 (de) |
| NO (1) | NO891122L (de) |
| NZ (1) | NZ228267A (de) |
| PT (1) | PT90027A (de) |
| ZA (1) | ZA891524B (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3689974T2 (de) * | 1985-03-14 | 1994-11-03 | Beecham Group Plc | Arzneimittel zur Behandlung von Emesis. |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| FR2698871B1 (fr) | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
| US6190691B1 (en) | 1994-04-12 | 2001-02-20 | Adolor Corporation | Methods for treating inflammatory conditions |
| JPH10500669A (ja) * | 1994-04-12 | 1998-01-20 | アルザ・コーポレーション | サイトカイン阻害薬に関するスクリーニング法 |
| US5962477A (en) * | 1994-04-12 | 1999-10-05 | Adolor Corporation | Screening methods for cytokine inhibitors |
| JP3492763B2 (ja) | 1994-06-03 | 2004-02-03 | エスエス製薬株式会社 | 白金錯体及びこれを含有する悪性腫瘍治療剤 |
| US6573282B1 (en) | 1995-09-12 | 2003-06-03 | Adolor Corporation | Peripherally active anti-hyperalgesic opiates |
| US5849761A (en) | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
| CA2385528C (en) | 1999-10-01 | 2013-12-10 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| AUPQ641100A0 (en) * | 2000-03-23 | 2000-04-15 | Australia Nuclear Science & Technology Organisation | Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents |
| PL370867A1 (en) * | 2001-09-24 | 2005-05-30 | Tosk, Inc. | Reduced toxicity cisplatin formulations and methods for using the same |
| ES2278115T3 (es) * | 2003-10-13 | 2007-08-01 | Zoser B. Nat.Rer.Dr. Salama | Composicion farmaceutica que comprende oxoplatino y sus sales. |
| US8956161B2 (en) * | 2008-11-04 | 2015-02-17 | Duane C Keller | Article and method for controlling oral-originated systemic disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3714159A (en) * | 1971-03-30 | 1973-01-30 | Janssen Pharmaceutica Nv | 2,2-diaryl-4-(4'-aryl-4'-hydroxy-piper-idino)-butyramides |
| US4175133A (en) * | 1977-02-18 | 1979-11-20 | United States Of America | 1,2-Diaminocyclohexane platinum (II) complexes having antineoplastic activity against L1210 leukemia |
| US4116963A (en) * | 1977-05-23 | 1978-09-26 | G.D. Searle & Co. | 3,3,3-triarylalkyl-4-phenylalkyl-4-hydroxy piperidines and related compounds |
| US4194045A (en) * | 1977-12-27 | 1980-03-18 | G. D. Searle & Co. | 1-(3,3-Diaryl-3-oxadiazolalkyl)-4-phenyl-4-piperidinomethanols and related compounds |
| CA1158558A (en) * | 1980-05-27 | 1983-12-13 | Terence J. Ward | Antidiarrhoeal agents |
| US4536386B1 (en) * | 1981-01-26 | 1995-03-07 | Robins Co Inc A H | Method of controlling emesis caused by cisplatin in cancer chemotherapy |
| GB8328218D0 (en) * | 1983-10-21 | 1983-11-23 | Johnson Matthey Plc | Oral compositions |
| US4599352A (en) * | 1984-03-01 | 1986-07-08 | The United States Of America As Represented By The Department Of Health And Human Services | Antineoplastic platinum (IV) complexes and compositions |
| DE3689974T2 (de) * | 1985-03-14 | 1994-11-03 | Beecham Group Plc | Arzneimittel zur Behandlung von Emesis. |
| GB8515845D0 (en) * | 1985-06-22 | 1985-07-24 | Beecham Group Plc | Treatment |
| GB8516083D0 (en) * | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
| US4793986A (en) * | 1987-02-25 | 1988-12-27 | Johnson Matthey, Inc. | Macromolecular platinum antitumor compounds |
-
1988
- 1988-03-16 GB GB888806224A patent/GB8806224D0/en active Pending
-
1989
- 1989-02-28 FI FI890951A patent/FI890951A/fi not_active IP Right Cessation
- 1989-02-28 ZA ZA891524A patent/ZA891524B/xx unknown
- 1989-03-03 EP EP89302158A patent/EP0339772A1/de not_active Ceased
- 1989-03-06 DK DK105889A patent/DK105889A/da unknown
- 1989-03-06 IL IL89502A patent/IL89502A0/xx unknown
- 1989-03-08 NZ NZ228267A patent/NZ228267A/en unknown
- 1989-03-08 AU AU31127/89A patent/AU613720B2/en not_active Expired - Fee Related
- 1989-03-14 JP JP1059842A patent/JPH0296523A/ja active Pending
- 1989-03-14 KR KR1019890003136A patent/KR890014107A/ko not_active Application Discontinuation
- 1989-03-15 NO NO89891122A patent/NO891122L/no unknown
- 1989-03-16 PT PT90027A patent/PT90027A/pt not_active Application Discontinuation
- 1989-03-16 US US07/324,054 patent/US4892735A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PT90027A (pt) | 1989-11-10 |
| FI890951A (fi) | 1989-09-17 |
| ZA891524B (en) | 1989-10-25 |
| IL89502A0 (en) | 1989-09-10 |
| AU3112789A (en) | 1989-09-21 |
| EP0339772A1 (de) | 1989-11-02 |
| NO891122D0 (no) | 1989-03-15 |
| KR890014107A (ko) | 1989-10-21 |
| GB8806224D0 (en) | 1988-04-13 |
| NZ228267A (en) | 1990-12-21 |
| FI890951A0 (fi) | 1989-02-28 |
| DK105889D0 (da) | 1989-03-06 |
| US4892735A (en) | 1990-01-09 |
| AU613720B2 (en) | 1991-08-08 |
| DK105889A (da) | 1989-09-17 |
| JPH0296523A (ja) | 1990-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69931766T2 (de) | Antitumorale mittel | |
| NO891122L (no) | Platinakoordinasjonsforbindelser og anvendelse av forbindelsene i kjemoterapi. | |
| US4871528A (en) | Pharmaceutical compositions having antineoplastic activity | |
| US20100240601A1 (en) | Coordination Complexes, Pharmaceutical Solutions Comprising Coordination Complexes, and Methods of Treating Patients | |
| US8299033B2 (en) | Iodo-hexose compounds useful to treat cancer | |
| IE80461B1 (en) | New compositions containing taxane derivatives | |
| EP0147926B1 (de) | Oral anwendbare Antikrebs-Zusammensetzungen | |
| DE69835824T2 (de) | Antitumorkombination aus 3-amino-1,2,4-benzotriazine 1,4-dioxid/paclitaxel/platin | |
| CA2297834C (en) | Chromium/biotin treatment of type ii diabetes | |
| EP1641460B1 (de) | Stabile pharmazeutische zusammensetzungen von 5,10-methylentetrahydrofolat | |
| US4628047A (en) | Agent for enhancing antitumor activity of antitumor agent | |
| GB8810173D0 (en) | Pharmaceutical compositions with anti-cancer activity & method for treatment of cancer | |
| EP1359979B1 (de) | Antikrebs-heilmittel welche substituierte pyrrole und paclitaxel enthält | |
| CA1248454A (en) | Cytidyl diphosphocholine-drug composition and process | |
| JP2557303B2 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| AU2007321218A1 (en) | Pyrrolo[1,2-a]imidazoledione effective in the treatment of peripheral neurotoxicity induced by chemotherapeutic agents | |
| US4925931A (en) | N-homocysteine thiolactonyl retinamido cobalamin and methods of use thereof | |
| CN108992463B (zh) | 一种治疗肺癌的组合物及药物制剂 | |
| EP2560639A2 (de) | Verfahren zur behandlung von prostatakrebs | |
| JP4078397B2 (ja) | 下痢の予防及び治療剤 | |
| EP1414829B1 (de) | Tumorhemmende cerverbindungen | |
| JPH0678227B2 (ja) | ４−エチル−２−ヒドロキシイミノ−５−ニトロ−３−ヘキセンアミド含有製剤用の安定化剤、安定化方法及び安定化された製剤 | |
| NZ525623A (en) | Pharmaceutical composition containing gaba analogs and an antiviral agent to treat shingles | |
| US4005204A (en) | Treatment of neoplasms in the brain with diamino dichloroalkyl pyrimidine | |
| CN113350370A (zh) | 聚乙二醇在预防和/或治疗肿瘤中的应用 |